Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × relugolix × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

pembrolizumab 7 Sunitinib 7 enfortumab vedotin 5 Gemcitabine 5 Cisplatin 5 enzalutamide 4 Nivolumab 4 Carboplatin 4 Abiraterone Acetate 4 avelumab 3 Prednisone 3 Ipilimumab 3 vinflunine 2 sacituzumab govitecan 2 niraparib 2 erdafitinib 2 entrectinib 2 cabozantinib 2 apalutamide 2 Pluvicto 2 Mitomycin 2 Leuprolide 2 Everolimus 2 Docetaxel 2 Axitinib 2 Androgen Antagonists 2 zimberelimab 1 relugolix 1 olaparib 1 luprolide acetate gel depot 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03085095 2022-01-18

HERO

Myovant Sciences GmbH

Phase 3 Completed

1,134 enrolled 38 charts 2 FDA

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡